NYSE · Healthcare · Biotechnology · USA
Biohaven Ltd is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.
Biohaven is a biopharmaceutical company discovering and developing treatments across immunology, neuroscience, and oncology. The company advances therapeutic candidates using proprietary platforms, including programs targeting ion channels for epilepsy, protein removal technologies for immune conditions, and agents addressing neuromuscular and metabolic disorders.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Biohaven Ltd stock.
Not valued: We cannot value this company yet.
17 more funds hold it; the full list is part of the paid plan.
135 more in this industry show a wider margin of safety.
We do not publish a verdict on BHVN yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-10-19 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.